Cargando…

Pasireotide in the Personalized Treatment of Acromegaly

The delay in controlling the disease in patients who do not respond to first-line treatment with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified in years, as every modification in the medical therapy requires some months to be fully evaluated. Considering thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puig-Domingo, Manel, Bernabéu, Ignacio, Picó, Antonio, Biagetti, Betina, Gil, Joan, Alvarez-Escolá, Cristina, Jordà, Mireia, Marques-Pamies, Montserrat, Soldevila, Berta, Gálvez, María-Angeles, Cámara, Rosa, Aller, Javier, Lamas, Cristina, Marazuela, Mónica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008639/ https://www.ncbi.nlm.nih.gov/pubmed/33796079 http://dx.doi.org/10.3389/fendo.2021.648411

Ejemplares similares

Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response
por: Gil, Joan, et al.
Publicado: (2022)

Data mining analyses for precision medicine in acromegaly: a proof of concept
por: Gil, Joan, et al.
Publicado: (2022)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
por: Gil, Joan, et al.
Publicado: (2021)

Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
por: Marques-Pamies, Montserrat, et al.
Publicado: (2023)

Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature
por: Araujo-Castro, Marta, et al.
Publicado: (2023)

Preference of acromegaly patients for treatment attributes in Spain
por: Fajardo, Carmen, et al.
Publicado: (2023)

Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated?
por: Soldevila, Berta, et al.
Publicado: (2021)

Age-Related Hormones Changes and Its Impact on Health Status and Lifespan
por: Biagetti, Betina, et al.
Publicado: (2023)

Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain
por: Biagetti, Betina, et al.
Publicado: (2022)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey
por: de Pablos-Velasco, Pedro, et al.
Publicado: (2019)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
por: Puglisi, Soraya, et al.
Publicado: (2020)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
por: Marques, Nelma Veronica, et al.
Publicado: (2023)

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
por: Bernabéu, Ignacio, et al.
Publicado: (2020)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly
por: Amarawardena, W K M G, et al.
Publicado: (2017)

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
por: Colao, Annamaria, et al.
Publicado: (2020)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
por: Lasolle, Hélène, et al.
Publicado: (2019)

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly
por: Fukunaga, Kensaku, et al.
Publicado: (2020)

Prevalence of acromegaly in patients with symptoms of sleep apnea
por: Sesmilo, Gemma, et al.
Publicado: (2017)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2021)

Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors
por: Gil, Joan, et al.
Publicado: (2023)

Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
por: Alvarez-Escola, Cristina, et al.
Publicado: (2016)

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
por: Wolf, Peter, et al.
Publicado: (2022)

Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
por: Gadelha, Mônica, et al.
Publicado: (2023)

Thyroid Hormone Upregulates Zinc-α(2)-glycoprotein Production in the Liver but Not in Adipose Tissue
por: Simó, Rafael, et al.
Publicado: (2014)

Metabolic Fingerprint of Acromegaly and Its Potential Usefulness in Clinical Practice
por: Biagetti, Betina, et al.
Publicado: (2019)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
por: Witek, Przemysław, et al.
Publicado: (2021)

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain
por: Lamas, Cristina, et al.
Publicado: (2023)

SAT-LB078 Acromegaly Disease Activity According to ACRODAT® in Spain: ACROVAL Study
por: Marazuela, Monica, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ksdask1462l89f9u2ri61jc5dn